title: Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial.
abstract: The largest randomized controlled trial (RCT) on the effect of FDG-PET on surgical management for metastatic colorectal adenocarcinoma to liver ("PET-CAM") reported only a modest change in surgical management (8%).
  
  
  OBJECTIVE
  To explore the relationship between prior chemotherapy and detection of metastatic disease on PET in patients from PET-CAM. Secondary aim: to determine whether centralized imaging interpretation could have impacted trial results.
  
  
  METHODS
  The study included 120 patients from a single institution. Local PET interpretation (PET-L) was recorded from the original database. Retrospective PET interpretation was performed independently by at least one additional reader (PET-C). The presence of extrahepatic disease (EHD) and significant additional liver metastases (=SALM), defined as metastases not originally planned for resection, was recorded. Patients were stratified to responders to recent chemotherapy (Group R) versus all others (Group O) according to surgical pathology and RECIST criteria.
  
  
  RESULTS
  Thirty-seven of 50 patients who received recent chemotherapy (<90 days) were responders (Group R). EHD was present in 30/120 (25%) patients. There was no difference in detection of EHD on PET-L (7/37;18.9%), PET-C (7/37;18.9%), and CT (4/37;10.8%) for Group R (p = 0.375), but in Group O more EHD was detected on both PET-L (15/83;18.1%) and PET-C (22/83;26.5%) than CT (8/83;9.6%); p = 0.039 and p < 0.001, respectively. For the entire cohort, PET-L and PET-C detected EHD and/or SALM not reported on CT in 14 (11.7%) and 22 (18.3%) patients.
  
  
  CONCLUSIONS
  The impact of recent chemotherapy on detection of colorectal metastases with PET suggests that the utility of PET in patient selection for liver resection in the prior PET-CAM-RCT may have been underestimated.
authors.affiliation: Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada. ur.metser@uhn.ca.
authors.forename: Ur
authors.initials: U
authors.lastname: Metser
authors.affiliation: Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
authors.forename: Jaydeep
authors.initials: J
authors.lastname: Halankar
authors.affiliation: Department of Clinical Programs, Cancer Imaging Program, Cancer Care Ontario, Toronto, ON, Canada.
authors.forename: Deanna
authors.initials: D
authors.lastname: Langer
authors.affiliation: Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
authors.forename: Ravi
authors.initials: R
authors.lastname: Mohan
authors.affiliation: Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
authors.forename: Douglas
authors.initials: D
authors.lastname: Hussey
authors.affiliation: Office of Research and Development, Joint Department of Medical Imaging, UHN, MSH, WCH, Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
authors.forename: Moshonov
authors.initials: M
authors.lastname: Hadas
authors.affiliation: Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
authors.forename: Shlomit
authors.initials: S
authors.lastname: Tamir
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Chemotherapy; Colorectal cancer; FDG; Liver metastases; PET